MarketVue®: Spinal Cord Injury (SCI)
The MarketVue®: Spinal Cord Injury (SCI) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Spinal Cord Injury (SCI) report is supported by 6 qualitative interviews with key opinion leaders, a quantitative survey with 26 U.S. physicians and secondary research.
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
Key companies mentioned:
• Kringle Pharma
• Eusol Biotech
• Acorda Therapeutics
• AbbVie
• Pharmazz
• Mitsubishi Tanabe Pharma
• ReNetX Bio
• Histocell
• Linage Cell Therapeutics
• AlaMab Therapeutics
• K Stem Cell (Biostar Stem Cell Research Institute)
• InVivo Therapeutics
Key drugs mentioned:
• Methylprednisolone
• KP-100IT
• ES 135
• Fampridine-SR
• Sovateltide / PMZ-1620 (Tycamzzi)
• Elezanumab
• MT-3921
• AXER-204
• HC016 Neurosave (FAB117-HC)
• OPC1
• ALMB-0166
• AstroStem
• Neuro-Spinal Scaffold
Please note: the online download version of this report is for a global site license.
- 1. DISEASE OVERVIEW
- A neurologic condition of loss of function and feeling
- Overview
- Table 1.1. American Spinal Cord Injury Association (ASIA) impairment scale
- Acute and chronic spinal cord injury
- Figure 1.2. symptoms of spinal cord injury
- 2. EPIDEMIOLOGY & PATIENT POPULATIONS
- Disease definition
- Figure 2.1. Prevalent cases of spinal cord injury by region, 2020
- Table 2.1 Prevalence of spinal cord injury by country, US and EU5, 2020
- Figure 2.2. Fast facts on spinal cord injury patient population.
- 3. CURRENT TREATMENT
- Treatment goals
- Figure 3.1. Primary goals of treating spinal cord injury
- Standard of care
- Figure 3.2. Percentage of patients who undergo surgery
- Diagnosis and treatment flow
- Figure 3.3. Diagnosis and treatment flow for spinal cord injury
- Drug-treatment rates
- Figure 3.4. Treating physicians and their patient load
- Is there a role for therapeutic hypothermia in SCI
- Figure 3.5. Percentage of acute SCI patients receiving therapeutic hypothermia
- Treating physicians and their patient load
- Figure 3.6. Professionals involved in spinal cord injury patient care
- Figure 3.7. Neurologist SCI patient load
- Must-know treatment dynamics
- Evolution of treatment
- Figure 3.8. Potential timeline of spinal cord injury market development
- 4. UNMET NEED
- Overview
- Figure 4.1. Top unmet needs in spinal cord injury
- Figure 4.2. Physician rankings of unmet needs in spinal cord injury
- Additional neurosurgeon commentary on unmet needs.
- Barriers to care
- Figure 4.3 Percent of neurologists ranking barrier as “impactful” to optimal spinal cord injury care.
- 5. PIPELINE ANALYSIS
- Overview
- Figure 5.1. Percentage of neurologists who rated emerging target or approach as “promising”
- Figure 5.2. Percentage of neurologists ranking product attribute among top three most important
- Figure 5.3. Number of emerging therapies addressing unmet needs in SCI
- Table 5.1. Emerging clinical-stage therapies for SCI
- Figure 5.4. Neurologists’ awareness of emerging spinal cord injury therapies
- 6. VALUE & ACCESS
- Overview
- Figure 6.1. Payer mix for spinal cord injury
- Healthcare costs and living expenses of SCI patients
- Figure 6.2. Yearly expenses (health care costs and living expenses)
- Table 6.1. Yearly expenses (health care costs and living expenses)
- Table 6.2. Categories of healthcare costs for SCI and areas of potential impact of new therapies
- 7. METHODOLOGY
- Primary market research methodology
- Epidemiology methodology
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook